Cancer Family
Malignant Digestive System Neoplasm
CI-CAN-00000229Explore in graph →
4,262 active trials43 approved drugs556 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000229Explore in graph →
Clinical trials
19,108 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (2,001)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07312422 | LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm Study | recruiting | Phase 1 / Phase 2 | 10 | Zhejiang Provincial People's HospitalOTHER | 1 | Jan 26, 2026 | clinicaltrials |
| NCT07364305 | HAIC Combined With Immune Therapy for Advanced, Non-Resectable ICC(Lalo) | recruiting | Phase 2 | 50 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Jan 23, 2026 |
| clinicaltrials |
| NCT05954429 | A Study to Explore the Third-line Treatment of Fruquintinib Combined With Serplulimab in Advanced Non-liver-limited Metastatic Colorectal Cancer: a Single-center, Phase 2 Study | recruiting | Phase 2 | 50 | Fudan UniversityOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT05978193 | Radiotherapy Combined With Immunochemotherapy in Metastatic Esophageal Squamous Cell Carcinoma(SCR-ESCC-01) | recruiting | Phase 2 | 100 | Shanghai Chest HospitalOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT03539822 | Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies(CAMILLA) | recruiting | Phase 1 / Phase 2 | 117 | Anwaar SaeedOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT05620628 | Ph2 Study of Savolitinib and Durvalumab (MEDI4736) Combination in Advanced MET Amplified Gastric Cancer(VIKTORY-2) | recruiting | Phase 2 | 25 | Jeeyun LeeOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT06468280 | Synergistic Effects of PD-1 Antibody and Chemotherapy/Targeted Therapy Followed by Surgery-centric Local Treatment in Patients With Limited-metastatic Gastric Cancer(ROSETTE) | recruiting | Phase 2 | 84 | Shanghai Zhongshan HospitalOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT07354711 | A First-in-human Study of 3H-10000 in Patients With Unresectable or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 170 | 3H Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 21, 2026 | clinicaltrials |
| NCT05366829 | Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma | recruiting | Phase 2 | 35 | Rutgers, The State University of New JerseyOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT02584244 | Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers | recruiting | Phase 1 / Phase 2 | 66 | Lumicell, Inc.INDUSTRY | 1 | Jan 16, 2026 | clinicaltrials |
| NCT07324824 | Sintilimab Plus Bevacizumab Biosimilar as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma | recruiting | Phase 2 | 37 | Sun Yat-sen UniversityOTHER | 1 | Jan 16, 2026 | clinicaltrials |
| NCT07347951 | A Single-center, Phase II Study on Efficacy & Safety of SCRT+CAPOX+Serplulimab+Bevacizumab for MSS Rectal Cancer | recruiting | Phase 2 | 30 | First Affiliated Hospital of Wenzhou Medical UniversityOTHER | 1 | Jan 16, 2026 | clinicaltrials |
| NCT05668884 | GEMOX Combined With Donafenib and Tislelizumab in Advanced Biliary Tract Carcinoma | recruiting | Phase 2 | 93 | Fudan UniversityOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT06864013 | SCRT Combined With Chemotherapy and Iparomlimab and Tuvonralimab in MSS or pMMR Patients With Locally Advanced Rectal Cancer | recruiting | Phase 2 | 116 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT03977233 | Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer | recruiting | Phase 2 | 45 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT06312982 | A Series of Neoadjuvant Chemoradiotherapy Combined With Immunotherapy for Locally Advanced Rectal Cancer | recruiting | Phase 2 / Phase 3 | 375 | Beijing Friendship HospitalOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT07337421 | Efcacy and Safety of Postoperative Adjuvant Hepatic Arterial Infusion Chemotherapy With mFOLFOX in Hepatocellular Carcinoma With High-risk Recurrence Factors | recruiting | Phase 2 | 30 | Northern Jiangsu People's HospitalOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT07337460 | Efficacy and Safety of Icaritin Combined With mFOLFOX in Postoperative HCC With High-risk Recurrence Factors | recruiting | Phase 2 | 30 | Northern Jiangsu People's HospitalOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT04689347 | 5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer. | recruiting | Phase 1 / Phase 2 | 27 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Jan 12, 2026 | clinicaltrials |
| NCT07334431 | Fruquintinib Combined With Trastuzumab and XELOX as First-line Treatment in Patients With HER2-positive Advanced Gastric Cancer | recruiting | Phase 1 / Phase 2 | 45 | Henan Cancer HospitalOTHER_GOV | 1 | Jan 12, 2026 | clinicaltrials |
| NCT07110571 | A Trial of Adebrelimab Plus (SHR-A1811/SHR-A1904 With Chemotherapy) or SHR-8068 as Treatment for Gastric/GEJ Cancer | recruiting | Phase 2 | 200 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 9, 2026 | clinicaltrials |
| NCT03322995 | Pancreatic Cancer Adaptive Neoadjuvant Chemotherapy Trial(PANC) | recruiting | Phase 2 | 125 | Medical College of WisconsinOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT07327034 | ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression | recruiting | Phase 2 | 141 | Abbisko Therapeutics Co, LtdINDUSTRY | 1 | Jan 8, 2026 | clinicaltrials |
| NCT07324304 | NWRD06 DNA Plasmid for HCC After Curative Resection. | recruiting | Phase 2 | 30 | Newish Technology (Beijing) Co., Ltd.INDUSTRY | 1 | Jan 7, 2026 | clinicaltrials |
| NCT05296681 | Microbiotic Product to Promote Microbiome Health and Improve Chemotherapy Delivery | recruiting | Phase 2 | 42 | Howard S. Hochster, MDOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT06526104 | Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas With Child-Pugh-B Cirrhosis | recruiting | Phase 2 | 32 | The University of Texas Health Science Center at San AntonioOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT07068763 | Node-Sparing Short-Course Radiation Combined With Capecitabine and PD-1/CTLA-4 for MSS Early Rectal Cancer(mRCAT-E) | recruiting | Phase 2 | 52 | Sir Run Run Shaw HospitalOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT07315854 | Iparomlimab and Tuvonralimab (QL1706) Combined With Chemotherapy for Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer | recruiting | Phase 2 | 32 | Beijing Friendship HospitalOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT06547736 | Exploratory Platform Research on Precision Therapy of Advanced Pancreatic Cancer | recruiting | Phase 2 | 160 | Fudan UniversityOTHER | 1 | Jan 5, 2026 | clinicaltrials |
| NCT07317414 | β-alanine in the Treatment of Advanced Hepatocellular Carcinoma | recruiting | Phase 2 | 158 | Peking Union Medical College HospitalOTHER | 1 | Jan 5, 2026 | clinicaltrials |
| NCT06590246 | A Study to Evaluate C-CAR031 in Glypican-3 (GPC3)+ Advanced/Recurrent Hepatocellular Carcinoma (HCC) | recruiting | Phase 1 / Phase 2 | 121 | Shanghai AbelZeta Ltd.INDUSTRY | 1 | Jan 2, 2026 | clinicaltrials |
| NCT04353375 | HMPL-453 Tartrate in Advanced Intrahepatic Cholangiocarcinoma | recruiting | Phase 2 / Phase 3 | 235 | HutchmedINDUSTRY | 1 | Dec 31, 2025 | clinicaltrials |
| NCT07311408 | SHR-1701 + Rivoceranib (± SHR-2554) in Advanced GC After First-Line Immunotherapy Failure(SHR-2554) | recruiting | Phase 2 | 40 | Jingdong ZhangOTHER | 1 | Dec 31, 2025 | clinicaltrials |
| NCT07310173 | Phase IIb Study of AST-3424 in Patients With AKR1C3-high Expressing Advanced Hepatocellular Carcinoma | recruiting | Phase 2 | 75 | Zhejiang Hisun Pharmaceutical Co. Ltd.INDUSTRY | 1 | Dec 30, 2025 | clinicaltrials |
| NCT06828380 | A Study Comparing Immunotherapy Alone Versus Immunotherapy Combined With Radiotherapy in Patients With Hepatocellular Carcinoma (HCC) With Vascular Invasion(IOPT) | recruiting | Phase 2 | 128 | National Cancer Center, KoreaOTHER_GOV | 1 | Dec 26, 2025 | clinicaltrials |
| NCT07279077 | Node-Sparing Low-Dose Radiotherapy Concurrent With Chemotherapy and PD-1 Inhibitor in pMMR/MSS High-Risk Locally Advanced Colon Cancer: A Prospective, Single-Arm, Phase II Trial(MODIFI-L) | recruiting | Phase 2 | 38 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Dec 26, 2025 | clinicaltrials |
| NCT04146298 | Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer | recruiting | Phase 1 / Phase 2 | 30 | Changhai HospitalOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT06640283 | Dynamic ctDNA Assessment in Cervical and Anal Canal Tumors: Optimizing Follow-up and Clinical Outcomes(ANA) | recruiting | Phase 2 | 150 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT06722183 | Futibatinib in Combination With (Chemo)Immunotherapy in Colorectal Cancer and Other Solid Tumor Entities(FUTURE) | recruiting | Phase 2 | 33 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT07300449 | A Prospective Multicenter Clinical Study of SCCG Protocol and ctDNA 5hmc in Predicting the Chemotherapy Sensitivity and Monitoring the Recurrence and Metastasis of Hepatoblastoma in Children and Adolescents | recruiting | Phase 2 | 100 | Sun Yat-sen UniversityOTHER | 1 | Dec 23, 2025 | clinicaltrials |
| NCT06161818 | Total Neoadjuvant Therapy for Lymph Node-positive Adenocarcinoma of the OESophagus and Oesophagogastric Junction(TNT-OES-2) | recruiting | Phase 2 | 216 | Erasmus Medical CenterOTHER | 1 | Dec 22, 2025 | clinicaltrials |
| NCT06934538 | First-in-human Trial of STC-1010, an Immunotherapy, in Patients With Unresectable Locally Advanced or Metastatic Colorectal Cancer | recruiting | Phase 1 / Phase 2 | 90 | Brenus PharmaINDUSTRY | 3 | Dec 22, 2025 | clinicaltrials |
| NCT07192068 | Clinical Trial Evaluating the Activity of Zanidatamab for the Treatment of Patients With Solid Tumors With an Alteration of the HER2 Gene.(AcSé HER2) | recruiting | Phase 2 | 105 | UNICANCEROTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT07282184 | Multimodal Deep Learning for Postoperative Liver Cancer Risk Stratification and Intervention | recruiting | Phase 1 / Phase 2 | 144 | Tongji HospitalOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT07291947 | PULSAR Combined With Immunotherapy and Chemotherapy | recruiting | Phase 1 / Phase 2 | 60 | Wang XinOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT05472948 | Surufatinib and Sintilimab in Combination With Capecitabine for Metastatic Adenocarcinoma of Small Intestine or Appendix Carcinoma | recruiting | Phase 2 | 36 | Sun Yat-sen UniversityOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT05959356 | Cetuximab and Envafolimab Plus mFOLFOXIRI as First-line Treatment for RAS/BRAF Wild-type, MSS, Unresectable Left-side Metastatic Colorectal Cancer(CEIL) | recruiting | Phase 2 | 198 | Sun Yat-sen UniversityOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT06730009 | Phase I/II Study: Allogeneic NK-cell Therapy With Chemotherapy for Post-Surgery PDA or Cholangiocarcinoma Patients | recruiting | Phase 1 / Phase 2 | 42 | Medigen Biotechnology CorporationINDUSTRY | 1 | Dec 17, 2025 | clinicaltrials |
| NCT07289997 | Iparomlimab and Tuvonralimab Combined With Apatinib and Irinotecan Hydrochloride for the Treatment of Advanced Alpha-fetoprotein-producing Gastric Cancer (AFPGC) | recruiting | Phase 2 | 39 | Hebei Medical University Fourth HospitalOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT07290010 | The Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy as the First-line Treatment for Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 25 | Hebei Medical University Fourth HospitalOTHER | 1 | Dec 17, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Jan 26, 2026source: clinicaltrials